U.S. Markets open in 7 hrs 45 mins

GNC Holdings, Inc. (GNC)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
7.25+0.18 (+2.55%)
At close: 4:02PM EDT
People also watch
VSIKORSEXPRFRANHLF
Full screen
Previous Close7.07
Open7.11
Bid0.00 x
Ask0.00 x
Day's Range7.11 - 7.37
52 Week Range6.51 - 28.11
Volume1,023,725
Avg. Volume3,252,587
Market Cap495.88M
Beta0.45
PE Ratio (TTM)-1.58
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.00 (0.00%)
Ex-Dividend Date2016-12-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube9 hours ago

    GNC Holdings, Inc. – Value Analysis (NYSE:GNC) : June 22, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives GNC Holdings, Inc. a score of 6. Our analysis is based on comparing GNC Holdings, Inc. with the following peers – Vitamin Shoppe, Inc., Walgreens Boots Alliance Inc, Rite Aid Corporation, Nutrastar International, Inc., Natural Health Trends Corp., Fresh Harvest Products, Inc., Herbalife Ltd. and Inergetics, Inc. ... Read more (Read more...)

  • GNC Holdings Continues to Gain from New GNC, Global Revenue
    Zacks2 days ago

    GNC Holdings Continues to Gain from New GNC, Global Revenue

    On Jun 20 2017, we issued an updated research report on Pittsburgh, PA-based GNC Holdings, Inc. (GNC).

  • American City Business Journals2 days ago

    NIH selection propels Cardax towards expansion

    The CEO of Cardax Inc. said the selection of the company's astaxanthin compound CDX-085 to take part in the National Institute on Aging's anti-aging interventions testing program will have positive implications for the Hawaii-based business. The program, among the top aging research programs in the U.S., is funded by the National Institutes of Health and only selects 4-5 compounds every year through extensive screening for their potential impact on lifespan extension and their ability to delay disease and dysfunction in mice at different ages. "The NIH is about a $38 billion annual budget and their science is very serious and credible and the fact that they would choose our compound I think speaks to the credibility of our whole program" Cardax President and CEO David Watumull told Pacific Business News.